跳至主要内容
临床试验/NCT00641212
NCT00641212已完成4 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis.

AstraZeneca0 个研究点目标入组 209 人开始时间: 2000年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
209
主要终点
Change in height over a 12 month period

研究概览

简要总结

The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
4 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • In the opinion of the investigator, is a candidate for treatment with nasal steroids based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids.
  • A documented history of at least one year of perennial allergic rhinitis.
  • A positive response to a skin prick test for perennial allergens that must be present in the subject's environment.
  • Height and weight within normal limits.

排除标准

  • Any disease which may affect growth
  • Sexual development later than Tanner stage I.
  • Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.

研究组 & 干预措施

1

Experimental

Budesonide

干预措施: Budesonide (Drug)

2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Change in height over a 12 month period

时间窗: 3 monthly

次要结局

  • Change in growth velocity over a 12 month period.(3 monthly)
  • Other safety - assessed by adverse event query(3 monthly)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验